H

    Harrow Health Inc (HROW)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $36.91
    -0.36 (-0.97%)

    Market Cap: $1.40B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    57%(21/37)
    Avg Surprise
    -126.38%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$0.27
    Range$-0.50 - $0.34
    3 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-0.02-107.5%
    60d ago$-0.23-186.2%
    30d ago$-0.23-186.2%
    7d ago$-0.24-190.0%
    Current$0.27
    Revenue Consensus
    $70M
    Range$63M - $76M
    8 analysts
    Dec 31, 2026
    EPS Consensus$0.58
    Range$0.44 - $0.72
    2 analysts
    Revenue Consensus
    $158M
    Range$148M - $162M
    8 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.58---
    Sep 26EST
    		-$0.27---
    Jun 26
    		$-0.34$-0.23-47.83%Miss-241.7%
    Mar 26
    		$-0.74$-0.33-124.24%Miss-94.7%
    Dec 25
    		$0.00N/A-100.00%Miss-100.0%
    Sep 25
    		$0.33$0.29+13.79%Beat+760.0%
    Jun 25
    		$0.24$0.04+500.00%Beat+500.0%
    Mar 25
    		$-0.38$0.01-3900.00%Miss-35.7%
    Dec 24
    		$0.40$0.13+207.69%Beat+260.0%
    Sep 24
    		$-0.05$0.07-171.43%Miss+44.4%
    Jun 24
    		$-0.06$-0.11+45.45%Beat-200.0%
    Mar 24
    		$-0.28$-0.25-12.00%Miss-833.3%
    Dec 23
    		$-0.25$-0.04-525.00%Miss-725.0%
    Sep 23
    		$-0.09$0.03-400.00%Miss+55.0%
    Jun 23
    		$-0.02$-0.04+50.00%Beat-300.0%
    Mar 23
    		$-0.03$-0.06+50.00%Beat-200.0%
    Dec 22
    		$0.04N/A+133.33%Beat+114.8%
    Sep 22
    		$-0.20$-0.03-566.67%Miss-600.0%
    Jun 22
    		$0.01$0.01+0.00%Beat-88.9%
    Mar 22
    		$0.03$-0.04+175.00%Beat-66.7%
    Dec 21
    		$-0.27$-0.04-575.00%Miss-775.0%
    Sep 21
    		$0.04$-0.03+233.33%Beat+0.0%
    Jun 21
    		$0.09$0.04+125.00%Beat+164.3%
    Mar 21
    		$0.09$0.02+350.00%Beat+325.0%
    Dec 20
    		$0.04$0.04+0.00%Beat-60.0%
    Sep 20
    		$0.04N/A+144.44%Beat+113.8%
    Jun 20
    		$-0.14$-0.17+17.65%Beat-180.0%
    Mar 20
    		$-0.04$-0.02-100.00%Miss+0.0%
    Dec 19
    		$0.10$0.06+66.67%Beat-87.0%
    Sep 19
    		$-0.29$-0.04-625.00%Miss-141.7%
    Jun 19
    		$-0.05$-0.06+16.67%Beat-145.5%
    Mar 19
    		$-0.04N/A+66.67%Beat+76.5%
    Dec 18
    		$0.77$0.34+126.47%Beat+692.3%
    Sep 18
    		$-0.12$-0.09-33.33%Miss+57.1%
    Jun 18
    		$0.11$-0.12+191.67%Beat+142.3%
    Mar 18
    		$-0.17$-0.16-6.25%Miss+19.0%
    Dec 17
    		$-0.13N/AN/ABeat+56.7%
    Sep 17
    		$-0.28$0.00N/ABeat+3.4%
    Jun 17
    		$-0.26$0.00N/ABeat-
    Mar 17
    		$-0.21$-0.19-10.53%Miss-
    Dec 16
    		$-0.30$-0.28-7.14%Miss-
    Sep 16
    		$-0.29$-0.34+14.71%Beat-

    Key Metrics

    Valuation
    P/E Ratio-72.37EV/EBITDA146.03x
    Price/FCF274.84xFCF Yield0.36%
    Profitability
    Profit Margin-13.50%Operating Margin-15.60%
    ROE-116.10%ROIC9.91%
    Financial Health
    Debt/Equity19.30xInterest Coverage0.96x
    Current Ratio2.24xQuick Ratio2.08x
    Trading Statistics
    Beta0.25Avg Volume561.09K
    52-Week High$54.8552-Week Low$28.54

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$39.73
    SMA 20$39.74
    SMA 50$41.17
    SMA 200$41.31
    EMA 10$39.03
    EMA 20$39.61
    EMA 50$39.89
    EMA 200$39.44

    MACD

    Line: -0.59Signal: -0.27Hist: -0.31

    ADX

    ADX: 18.0+DI: 17.2-DI: 29.2

    Aroon & PSAR

    Aroon Up44.0
    Aroon Down100.0
    PSAR$42.67

    Bollinger Bands

    Upper Band$42.31
    Lower Band$37.17
    %B Position1295%(Upper)
    Band Width-0.05

    RSI (14-Day)

    Neutral
    38.4

    Momentum Oscillators

    Stoch %K9.8
    Stoch %D21.6
    Williams %R-89.8
    ROC (10d)-6.5%
    Momentum-2.56
    CCI (20d)-242.8
    MFI (14d)29.3

    Volatility Measures

    ATR (14d)$1.99(5.4%)
    StdDev (20d)1.29
    Hist Vol41.2%(High)

    Volume Flow

    VWAP$36.87
    OBV8.9M
    AD Line-8.4M
    CMF (20d)-0.137

    Volume Metrics

    Avg Vol (20d)569.1K
    Vol Ratio0.7x
    VWMA (20d)$39.76

    Pivot Points

    R3$40.09
    R2$39.44
    R1$38.36
    Pivot Point$37.71
    S1$36.63
    S2$35.98
    S3$34.90

    Advanced Oscillators

    TSI-8.82
    Ultimate Osc35.8
    KST-34.69

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$70.66M$44.20M$89.09M$71.64M$63.74M$47.83M$66.83M$49.26M$48.94M$34.59M$36.35M$34.27M
    Cost of Revenue$20.30M$17.16M$18.47M$17.71M$16.23M$15.52M$14.13M$12.02M$12.54M$10.55M$11.30M$10.07M
    Gross Profit$50.36M$27.05M$70.62M$53.93M$47.51M$32.31M$52.70M$37.24M$36.40M$24.03M$25.05M$24.20M
    Operating Expenses$61.37M$49.13M$55.03M$39.18M$36.10M$43.54M$39.80M$35.92M$34.87M$30.96M$29.93M$22.45M
    R&D$8.07M$5.89M$11.72M$3.32M$2.87M$3.03M$4.75M$2.27M$3.05M$2.15M$3.34M$1.42M
    SG&A$53.30M$43.23M$43.31M$35.86M$33.23M$40.51M$34.79M$33.65M$31.82M$28.81M$26.21M$21.03M
    Operating Income$-11,007,000$-22,080,000$15.59M$14.75M$11.41M$-11,232,000$12.90M$1.32M$1.53M$-6,928,000$-4,875,000$1.74M
    Interest Income$0$0$0$0$0$0$0$0$-1,923,000$-1,248,000$416,000$1.35M
    Interest Expense$6.26M$5.50M$5.19M$13.79M$6.41M$6.55M$6.38M$5.53M$5.47M$5.42M$5.12M$5.75M
    Income Before Tax$-17,270,000$-27,577,000$10.40M$1.02M$5.00M$-17,780,000$6.26M$-4,200,000$-5,818,000$-13,565,000$-9,683,000$-2,852,000
    Income Tax Expense$0$25,000$0$0$0$0$0$20,000$655,000$0$-535,000$1.54M
    Net Income$-17,270,000$-27,602,000$6.63M$1.02M$5.00M$-17,780,000$6.78M$-4,220,000$-6,473,000$-13,565,000$-9,148,000$-4,391,000
    EBITDA$-4,620,000$-16,045,000$20.72M$20.25M$17.41M$-5,266,000$18.40M$5.07M$5.75M$-2,746,000$-1,104,000$5.67M
    EBIT$-11,007,000$-22,080,000$15.58M$14.81M$11.40M$-11,232,000$12.64M$1.32M$1.58M$-6,902,000$-4,975,000$1.55M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about HROW

    News

    ETFs Investing in Harrow, Inc. Stocks

    This article provides a comprehensive list of Exchange Traded Funds (ETFs) that hold Harrow, Inc. (HROW) stocks, sorted by market value. It details various ETFs, including those focused on small-cap, health care, and pharmaceutical sectors, along with their issuers, management styles, expense ratios, and performance metrics, offering investors insights into diverse investment opportunities with HROW exposure.

    TradingView•8/22/26•
    Neutral

    Harrow’s Iheezo Cuts Eye-Injection Discomfort by More Than Half

    Harrow Inc. announced positive results from a clinical study on its ocular anesthetic, IHEEZO, showing a significant 58% reduction in discomfort for patients undergoing intravitreal injections compared to proparacaine. This improvement in patient comfort could enhance compliance with eye treatments, according to William Blair analysts who maintain an Outperform rating on Harrow stock due to attractive long-term growth prospects.

    Sahm•8/22/26•
    Bullish

    Harrow (NASDAQ: HROW) CSO sells 11,250 shares in August option trade

    Harrow, Inc.'s Chief Scientific Officer, Amir Shojaei, sold 11,250 shares of common stock on August 14, 2026, after exercising employee stock options. The sale had an aggregate market value of approximately $450,000, and the Form 144 filing was delayed due to an administrative oversight. There were 37,487,850 shares of common stock outstanding at the time of the notice.

    Stock Titan•8/21/26•
    Neutral

    Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections

    Harrow (Nasdaq: HROW) announced positive results from a study showing that its ophthalmic gel, IHEEZO® (chloroprocaine hydrochloride ophthalmic gel) 3%, significantly reduced patient-reported discomfort during and after intravitreal injections. Patients experienced approximately 58% less discomfort in the IHEEZO-treated eye compared to those treated with proparacaine, with the largest differences observed immediately post-injection. These findings suggest IHEEZO could improve the patient experience for the millions of intravitreal injections performed annually.

    Sahm•8/21/26•
    Bullish

    Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections

    Harrow (Nasdaq: HROW) announced positive results from a study evaluating IHEEZO® (chloroprocaine hydrochloride ophthalmic gel) 3% in patients undergoing bilateral intravitreal injections. The study showed that patients reported approximately 58% less overall discomfort in the IHEEZO-treated eye compared to the eye treated with proparacaine ophthalmic solution 0.5%. These findings suggest IHEEZO offers a significant improvement in patient comfort following a common ophthalmic procedure.

    GlobeNewswire•8/20/26•
    Bullish

    Frequently Asked Questions About HROW

    Does HROW pay dividends?
    Harrow Health Inc (HROW) does not currently pay a regular dividend.
    What is HROW's market cap?
    Harrow Health Inc (HROW) has a market capitalization of $1.40B with a current stock price of $36.91.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In